Specialty Pharmacy

Out-of-pocket costs projected to drop from 11.6% in 2013 to 10% in 2024.

Treatment uses photodynamic therapy with compounds that make cancer cells vulnerable to reactive oxygen species.

Researchers seek to improve treatment for autoimmune diseases, including rheumatoid arthritis, gout, Crohn's disease, and lupus.

A 10-second assessment may be as effective as more complex tests.

The FDA is considering expanding the use of Merck's pembrolizumab as a first-line treatment for advanced melanoma.

More companies are requiring prior authorization before specialty drugs are purchased under employer health plan.

Medicare Part D contracting transparencies among issues that prompted action.

Rheumatoid arthritis treatment remains consistently well tolerated over long-term evaluation.

Nephropathic cystinosis drug Procysbi now available in delayed-release capsules for young children.

Depression and fatigue loom as issues to overcome for patients with multiple sclerosis.

Women and individuals who suffered childhood sexual abuse among most vulnerable IBD patients.

Specialty pharmacies need to carefully evaluate multiple aspects of manufacturer-sponsored free product programs.

Study finds coffee consumption improves survival odds in some patients.

Research may lead to a gel that instantly destroys viral particles.

In the long wake of a deadly meningitis outbreak from tainted drugs distributed by a compounding pharmacy in Massachusetts, state regulators have been increasing their inspections of pharmacies with complaints.

Patients with any type of health insurance receive preventive care for chronic diseases at rates up to 3 times higher than their uninsured counterparts, the US Centers for Disease Control and Prevention has found.

Debate continues around eligibility requirements for pricey new high cholesterol drug class.

Novel kinase cascade found to regulate cancer growth.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses URAC specialty practice standards.

Sprycel label now includes 5-year first-line efficacy and safety data in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

Low bleeding rates found with intervals of up to 2 weeks between infusions.

Company alleged to have marketed products as viable treatments for cancer, malaria, herpes, and heart disease.

Experimental drug shows promise in recent study.

The FDA has approved Baxter and Water Street's cefazolin 2 g injection in a frozen premix, providing another cephalosporin antibacterial option for preoperative prophylaxis treatment.

Many people who test negative for BRCA1 and BRCA2 harbor other harmful genetic mutations.

Reaching the gap impacts access to medication and influences adherence.

Biologics are changing how clinicians make treatment choices.

Outpatient pharmacy spending totaled 20% of total health care expenditures.